替罗非班联合依达拉奉对进展性脑梗死患者脑血流量及神经损伤的影响

Effect of Tirofiban Combined with Edaravone on Cerebral Blood Flow and Nerve Injury in Patients with Progressive Cerebral Infarction

目的分析替罗非班联合依达拉奉治疗进展性脑梗死患者中的效果。方法选择我院2021年8月—2022年8月收诊的72例进展性脑梗死患者为研究对象,按随机数字表法分为两组,各36例。对照组采用依达拉奉治疗,观察组在对照组基础上加用替罗非班治疗,均持续治疗2周。对比两组脑动脉收缩期血流速度峰值(Vs)、舒张末期血流速度(Vd)、平均血流速度(Vm)、美国国立卫生院卒中量表(NIHSS)评分、血小板聚集率(PAgT)、血小板黏附率(PAdT)、血小板P选择素(P-selectin)及不良反应。结果治疗2周后,观察组Vs(87.19±9.14)cm/s、Vd(29.82±5.43)cm/s、Vm(55.84±8.21)cm/s,分别快于对照组的(80.21±8.59)cm/s、(25.28±5.16)cm/s、(50.61±7.47)cm/s,组间差异有统计学意义(P<0.05)。治疗1、2周后,观察组NIHSS评分为(7.46±1.17)分、(4.07±0.81)分,均低于对照组的(10.05±2.11)分、(6.35±1.04)分,组间差异有统计学意义(P<0.05)。治疗2周后,观察组PAgT(26.87±2.63)%、PAdT(33.76±3.48)%、P-selectin(9.22±2.18)μg/L,分别低于对照组的(31.42±3.14)%、(36.87±3.52)%、(12.41±3.05)μg/L,组间差异有统计学意义(P<0.05)。两组不良反应发生率相比,差异无统计学意义(P>0.05)。结论替罗非班联合依达拉奉治疗进展性脑梗死患者的疗效确切,能够增加其脑血流量,减轻神经功能损伤,改善血小板功能,且不良反应较少,值得临床进行大力的推广。

Objective To analyze the effect of Tirofiban combined with Edaravone in the treatment of patients with progressive cerebral infarction.Methods 72 patients with progressive cerebral infarction admitted to the hospital from August 2021 to August 2022 were selected as the research objects and divided into two groups according to random number table method,with 36 cases in each group.The control group was treated with Edaravone,and the observation group was treated with tirofiban on the basis of the control group,and the treatment lasted for 2 weeks.Systolic peak blood flow velocity(Vs),end-diastolic blood flow velocity(Vd),mean blood flow velocity(Vm),National Institutes of Health Stroke Scale(NIHSS)score,platelet aggregation rate(PAgT),platelet adhesion rate(PAdT),platelet P-selectin(P-selectin)and adverse reactions of the two groups were compared.Results After 2 weeks of treatment,the observation group Vs(87.19±9.14)cm/s,Vd(29.82±5.43)cm/s,Vm(55.84±8.21)cm/s,respectively,which were faster than the control group(80.21±8.59)cm/s,(25.28±5.16)cm/s and(50.61±7.47)cm/s,and the differences between groups were statistically significant(P<0.05).After 1 and 2 weeks of treatment,NIHSS scores of the observation group were(7.46±1.17)points and(4.07±0.81)points,which were lower than(10.05±2.11)points and(6.35±1.04)points of the control group,and the differences were statistically significant between the two grups(P<0.05).After 2 weeks of treatment,PAgT(26.87±2.63)%,PAdT(33.76±3.48)%,P-selectin(9.22±2.18)μg/L in the observation group,respectively,which were lower than(31.42±3.14)%,(36.87±3.52)%,(12.41±3.05)μg/L of control group,and the differences between groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Tirofiban combined with Edaravone has definite efficacy in the treatment of patients with progressive cerebral infarction,which can increase cerebral blood flow,reduce nerve function injury,improve platelet function,and has fewer adverse reactions,which is worthy of clinical promotion.